Product logins

Find logins to all Clarivate products below.


Dr Dilpreet Singh, MD Ortho

Partner & Head JAPAC Consulting, Clarivate Consulting Services

Dr. Dilpreet Singh, is an experienced life sciences consultant with over 20 years in pharma & biotech. A surgeon turned management consultant turned entrepreneur and back to consulting, he has breadth of experience across the pharma & life sciences segments including operations & strategy execution.

Dilpreet was a Sr. Principal at L.E.K. Consulting and IQVIA (earlier IMS Health), leading the consulting practice across the SEA and APAC region. He has been a trusted advisor to clients across Market access & Go-to-market strategies, product and portfolio lifecycle management from R&D investments to licensing or launch, along with corporate strategies such as M&A, divestment and partnerships. He also has industry experience, most recently at Cerecin, being the COO of the neuro focused biotech with P3 asset in Alzheimer’s Disease and also at Johnson & Johnson earlier.

He has also been a speaker at industry leading events (eg APACMed, ESMO Asia etc), with published thought leadership across new and emerging technologies, and commercial models in biopharma and medical devices space

Dilpreet is passionate about technology in life sciences and founded Juvoxa, a health-tech patient-centric care platform to drive evidence driven outcomes in specialty care. He is actively involved in startup ecosystem in the region, and is an active investor, mentor and advisor to some promising early-stage startups in the region as well.

Dilpreet holds an MBA from the Indian School of Business, Hyderabad and Masters in Surgery (Orthopedics) from All India Institute of Medical Sciences, Delhi

Latest news

News November 24, 2025
Clarivate Launches Derwent Patent Monitor to Enable Fast and Accurate Decision-making with AI

New enterprise solution streamlines IP and R&D patent reviews and accelerates freedom to operate, patentability, and infringement related decisions London, U.K. November 24, 2025. Clarivate Plc (NYSE:CLVT), a leading global provider…

News November 18, 2025
Clarivate Report Reveals 85% Adoption of AI Across the Intellectual Property Ecosystem

Comfort with AI in IP workflows increased from 57% in 2023 Trust remains critical with 65% of attorneys citing Governance as top barrier to scale London, U.K. November 18, 2025:…

News November 13, 2025
Clarivate RiskMark Wins 2025 LegalTech Breakthrough Award For “LegalTech Predictive AI Solution of the Year”

Annual awards program recognizes companies and products driving innovation in the global legal technology industry AI-powered RiskMark delivers near-instant, data-backed insights London, U.K. November 13, 2025. Clarivate Plc (NYSE:CLVT), a…

Related resources

Managing uncertainty for medicine in Washington Managing uncertainty for medicine in Washington
Blog May 15, 2025
Managing uncertainty for medicine in Washington
Clinical research Early drug development research Market Access Pharma Portfolio strategy Research Research and development Research commercialization Research evaluation and management
Navigating uncertainty: What’s keeping healthcare execs up at night in this new era Navigating uncertainty: What’s keeping healthcare execs up at night in this new era
Blog April 2, 2025
Navigating uncertainty: What’s keeping healthcare execs up at night in this new era
Market Access Pharma Portfolio strategy Regulatory Research commercialization
Five Medtech Trends to Watch in 2025 Five Medtech Trends to Watch in 2025
Blog February 11, 2025
Five Medtech Trends to Watch in 2025
Medical technology Medtech Medtech Resource Center
The trends to watch in 2025 The trends to watch in 2025
Blog January 8, 2025
The trends to watch in 2025